Literature DB >> 9507238

Hepatic cholesterol metabolism in experimental nephrotic syndrome.

A al-Shurbaji1, E Humble, M Rudling, B Lindenthal, L Berglund.   

Abstract

Hypercholesterolemia is a consistent feature of the nephrotic syndrome. However, the mechanisms underlying this perturbation are unclear. In the present work, we have investigated different factors that influence hepatic cholesterol metabolism using the nephrotic rat as a model. The induction of nephrosis resulted in a severe and sustained hypercholesterolemia. However, no effect on the rate-limiting enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, could be detected. Further, plasma lathosterol/cholesterol ratio, a measure of cholesterol synthesis, was not altered. Also, plasma levels of mevalonate, both a substrate for cholesterogenesis beyond the rate-limiting step and a marker for cholesterol synthesis, did not differ between control rats and those with established hypercholesterolemia. There was no detectable change in the expression of low density lipoprotein (LDL) receptor between the two experimental groups. We conclude that the early increase in cholesterol synthesis reported after the induction of nephrosis is not necessary for the maintenance of hypercholesterolemia. Established hypercholesterolemia of the nephrotic syndrome seems to represent a steady state in which neither enhanced hepatic cholesterol synthesis nor retarded LDL cholesterol clearance is of major importance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507238     DOI: 10.1007/s11745-998-0192-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  33 in total

1.  Metabolic channeling in experimental nephrosis. II. Lipide metabolism.

Authors:  J B MARSH; D L DRABKIN
Journal:  J Biol Chem       Date:  1955-02       Impact factor: 5.157

2.  Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states.

Authors:  M S Brown; J L Goldstein; J M Dietschy
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

3.  Extrarenal complications of the nephrotic syndrome.

Authors:  D B Bernard
Journal:  Kidney Int       Date:  1988-06       Impact factor: 10.612

4.  Ischaemic heart-disease as a complication of nephrotic syndrome.

Authors:  G M Berlyne; N P Mallick
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

5.  Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol.

Authors:  W C Duane
Journal:  J Lipid Res       Date:  1995-02       Impact factor: 5.922

Review 6.  Lipoprotein metabolism in experimental nephrosis.

Authors:  J B Marsh
Journal:  J Lipid Res       Date:  1984-12-15       Impact factor: 5.922

7.  Experimental nephrotic syndrome induced in the rat by puromycin aminonucleoside: hepatic synthesis of neutral lipids and phospholipids from 3H-water and 3H-palmitate.

Authors:  E Gherardi; S Calandra
Journal:  Lipids       Date:  1980-02       Impact factor: 1.880

8.  The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat.

Authors:  T A Golper; K R Feingold; M H Fulford; M D Siperstein
Journal:  J Lipid Res       Date:  1986-10       Impact factor: 5.922

9.  Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.

Authors:  N D Vaziri; K H Liang
Journal:  Kidney Int       Date:  1995-12       Impact factor: 10.612

10.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

View more
  4 in total

1.  Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats.

Authors:  Yunfeng Zhou; Xiaoyan Zhang; Lihong Chen; Jing Wu; Huaixin Dang; Mingfen Wei; Yanbo Fan; Yahua Zhang; Yi Zhu; Nanping Wang; Matthew D Breyer; Youfei Guan
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-09

2.  Attenuation of Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) Rats with a Combination of Chinese Herbs (Tangshen Formula).

Authors:  Haojun Zhang; Ping Li; Frank J Burczynski; Yuewen Gong; Patrick Choy; Hong Sha; Jing Li
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-17       Impact factor: 2.629

3.  Effects of dietary protein and fat contents on renal function and inflammatory cytokines in rats with adriamycin-induced nephrotic syndrome.

Authors:  Su Yeon Kim; A Young Lim; Su Kyung Jeon; In Seok Lee; Ryowon Choue
Journal:  Mediators Inflamm       Date:  2011-05-24       Impact factor: 4.711

4.  Effect of Poria cocos on Puromycin Aminonucleoside-Induced Nephrotic Syndrome in Rats.

Authors:  So Min Lee; Yun Jung Lee; Jung Joo Yoon; Dae Gill Kang; Ho Sub Lee
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-07       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.